Martínez Carmona, MarinaIzquierdo Barba, IsabelColilla Nieto, MontserratVallet Regí, María Dulce Nombre2023-06-172023-06-172019-07-031742-706110.1016/j.actbio.2019.07.001https://hdl.handle.net/20.500.14352/13447RESEARCHER ID N-3992-2014 (Marina Martínez Carmona) ORCID 0000-0002-2026-6266 (Marina Martínez Carmona) RESEARCHER ID M-9921-2014 (Isabel Izquierdo Barba) ORCID 0000-0002-4139-4646 (Isabel Izquierdo Barba) RESEARCHER ID N-4628-2014 (Montse Colilla Nieto) ORCID 0000-0003-1961-4160 (Montse Colilla Nieto) RESEARCHER ID M-3378-2014 (María Vallet Regí) ORCID 0000-0002-6104-4889 (María Vallet Regí)The ability of bacteria to form biofilms hinders any conventional treatment for chronic infections and has serious socio-economic implications. For this purpose, a nanocarrier capable of overcoming the barrier of the mucopolysaccharide matrix of the biofilm and releasing its loadedantibiotic within this matrix would be desirable. Herein, we developed a new nanosystem based on levofloxacin (LEVO)-loaded mesoporous silica nanoparticles (MSNs) decorated with the lectin concanavalin A (ConA). The presence of ConA promotes the internalization of this nanosystem into the biofilm matrix, which increases the antimicrobial efficacy of the antibiotic hosted within the mesopores. This nanodevice is envisioned as a promising alternative to conventional treatments for infection by improving the antimicrobial efficacy and reducing side effects.engjournal articlehttps://doi.org/10.1016/j.actbio.2019.07.001http://www.ucm.es/valletregigroupopen access54666615.46BiofilmBacterial infectionLectinMesoporous Silica NanoparticlesNanomedicineSynergistic CombinationTargetingMaterialesQuímica inorgánica (Farmacia)3312 Tecnología de Materiales